The EMA’s CHMP backed Novo’s hemophilia A preventive therapy, recommending the drug for approval, alongside positive opinions for seven other new medicines and 11 label expansions. The CHMP recommendations are a key step in the EU authorization process and often precede formal European Commission decisions. The package also reflects the committee’s breadth across oncology, immunology, and specialty care areas, with label expansions indicating regulators are continuing to refine indications based on accumulated clinical evidence. For hemophilia competitors, the opinion increases pressure to demonstrate durability, bleeding-rate reduction, and safety in pivotal and post-authorization datasets.